Journal of American Medical Association (subscription) - Bridget M. Kuehn - 14 hours ago
... of long-acting and sustained-release opioid products as a prerequisite to receiving a Schedule II prescribing license from the Drug Enforcement Agency. ...
6129930 ("Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia at Night," issued October 10, 2000), 6406715 ("Intermediate ...
Iluvien will be the second product to enter the expanding market of sustained release intraocular drug delivery. It is similar to Ozurdex (Allergan) in that ...
The patent entitled "Sustained-Release Bupropion and Bupropion/Mecamylamine Tablets" discloses the formulation of pharmaceutical tablets containing ...
Debiopharm developed and registered the 1- and 3-month sustained release formulations of triptorelin embonate in Europe and the US The active substance in ...
The use of the FTD technology will improve pharmaceutical solubility, enhance chemical stability, add a sustained release property and expand available ...
Ipsen and Debiopharm have revealed that a 22.5 mg six-month sustained-release formulation of Decapeptyl (triptorelin embonate1) has been launched in France. ...
Email this story